These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Targeting binding partners of the CBFβ-SMMHC fusion protein for the treatment of inversion 16 acute myeloid leukemia. Richter L; Wang Y; Hyde RK Oncotarget; 2016 Oct; 7(40):66255-66266. PubMed ID: 27542261 [TBL] [Abstract][Full Text] [Related]
3. Chemical biology. A small-molecule inhibitor of the aberrant transcription factor CBFβ-SMMHC delays leukemia in mice. Illendula A; Pulikkan JA; Zong H; Grembecka J; Xue L; Sen S; Zhou Y; Boulton A; Kuntimaddi A; Gao Y; Rajewski RA; Guzman ML; Castilla LH; Bushweller JH Science; 2015 Feb; 347(6223):779-84. PubMed ID: 25678665 [TBL] [Abstract][Full Text] [Related]
4. HDAC1 Is a Required Cofactor of CBFβ-SMMHC and a Potential Therapeutic Target in Inversion 16 Acute Myeloid Leukemia. Richter LE; Wang Y; Becker ME; Coburn RA; Williams JT; Amador C; Hyde RK Mol Cancer Res; 2019 Jun; 17(6):1241-1252. PubMed ID: 30814129 [TBL] [Abstract][Full Text] [Related]
5. c-Myc overcomes cell cycle inhibition by CBFbeta-SMMHC, a myeloid leukemia oncoprotein. Bernardin F; Yang Y; Civin CI; Friedman AD Cancer Biol Ther; 2002; 1(5):492-6. PubMed ID: 12496475 [TBL] [Abstract][Full Text] [Related]